Neoplasms
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research
Pfizer Taps Novartis Veteran Jeffrey Legos to Lead Oncology R&D Efforts
Pfizer, Jeffrey Legos, oncology, R&D, leadership, cancer research, pharmaceutical industry
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts
Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment
World Cancer Day 2025: Innovations in Prevention, Detection, and Treatment
cancer research, immunotherapy, early detection, AI in oncology, novel therapies, clinical trials, personalized medicine
ITM’s Radiopharmaceutical ITM-11 Shows Promising Results in Phase III COMPOSE Trial for Advanced Neuroendocrine Tumors
ITM-11, neuroendocrine tumors, GEP-NETs, COMPOSE trial, targeted radionuclide therapy, 177Lu-edotreotide
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
GE HealthCare and UCSF Collaborate on Innovative Imaging Solutions for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Cancer Imaging, Neurodegenerative Disease Imaging, Precision Oncology, Brain Health, Joint Research Program, Care Innovation Hub
GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases
GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.
Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies
Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology